The science, and the care team that goes with it
Incretin-based medicines are the most consequential development in metabolic health in a generation — and the most misrepresented. This is what the evidence supports, what it does not, and how supervised care works here.
- Verified clinicians
- Scope of practice enforced
- Maintenance planned from day one
The compounds
Approved, and not approved — the distinction that matters most
These molecules are often discussed as one category. Regulators do not treat them as one category, and neither do we.
Semaglutide
EstablishedGLP-1 receptor agonism in type 2 diabetes, weight management and cardiovascular risk.
Last reviewed 28 Jul 2026
Tirzepatide
EstablishedDual GIP and GLP-1 receptor agonism in type 2 diabetes and obesity.
Last reviewed 20 Jul 2026
Retatrutide
PromisingTriple GIP, GLP-1 and glucagon receptor agonism in obesity and metabolic disease.
Last reviewed 30 Jul 2026
Straight answers
The five questions people actually ask
- Is this a medicine or a supplement?
- Approved GLP-1 medicines are prescription drugs with a specific label, manufacturer and indication. They are not supplements, and they are not interchangeable with compounded or grey-market material sold under the same molecule name.
- What does the evidence actually support?
- For approved products within their approved indications, the evidence is strong — large randomised trials with cardiovascular outcome data. That strength does not automatically transfer to unapproved compounds in the same class, or to use outside the studied population.
- What happens when you stop?
- Substantial weight regain after discontinuation is consistently reported. This is arguably the most important practical question in the field, and it is why a maintenance plan matters more than the rate of initial loss.
- What about muscle?
- Lean mass is lost alongside fat mass. Resistance training and adequate protein are the standard countermeasures, and they are a large part of why coaching sits alongside prescribing on this platform.
- Why does supply matter so much?
- Compounded and grey-market products have been linked to dosing errors and adverse events in several jurisdictions. The molecule and the product you can actually obtain are two different risk questions.
How care works here
A doctor prescribes. A coach supports. Neither does the other's job.
The failure mode in this market is coaching that drifts into prescribing, and prescribing with no support attached. We separate the two explicitly and hold them in one shared plan.
- 01
Clinical review
A verified physician reviews your history, medications, bloodwork and goals. If a medicine is not appropriate, they say so.
- 02
A shared plan
Your clinician sets what matters and what to watch. Nutrition and training support are built around it, not invented separately.
- 03
Ongoing support
A coach works with you week to week on training, protein, sleep and adherence — inside a written scope of practice.
- 04
Review and maintenance
Regular clinical review, and an explicit plan for what happens when you come off. That plan exists from day one.